CSPIA
NBIX icon

Cary Street Partners Investment Advisory’s Neurocrine Biosciences NBIX Stock Holding History

Cary Street Partners Investment Advisory’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-121
Closed -$13.6K – 1385
2023
Q3 		$13.6K Hold
121
– – ﹤0.01% 1217
2023
Q2 		$11.4K Buy
121
+12
+11% +$1.17K ﹤0.01% 1205
2023
Q1 		$11K Hold
109
– – ﹤0.01% 1122
2022
Q4 		$13K Buy
+109
New +$12.8K ﹤0.01% 1077

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Cary Street Partners Investment Advisory's NBIX Position: Q4 2023 in Review

Cary Street Partners Investment Advisory sold out of Neurocrine Biosciences (NBIX) in Q4 2023, closing a stake of 121 shares — an estimated $13.6K sold.

Cary Street Partners Investment Advisory first reported a position in NBIX in Q4 2022 and held it in 4 quarters. The position peaked at $13.6K in Q3 2023. 555 funds tracked by Wall St. Rank hold NBIX as of Q4 2023.

  • Cary Street Partners Investment Advisory reported no remaining Neurocrine Biosciences position as of Q4 2023 after selling out during the quarter.
  • Cary Street Partners Investment Advisory sold 121 Neurocrine Biosciences shares in Q4 2023, an estimated $13.6K.
  • Cary Street Partners Investment Advisory first reported a position in Neurocrine Biosciences in Q4 2022 and held it in 4 quarters.
  • Cary Street Partners Investment Advisory's Neurocrine Biosciences position peaked at $13.6K in Q3 2023.
  • 555 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q4 2023.

Based on Cary Street Partners Investment Advisory's 13F filing for Q4 2023, filed 5 Feb 2024.